Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients

NCT04552613 NA COMPLETED

This study is a randomized, multicenter clinical study ，which is designed to compare the efficacy of the safety and efficacy of treatment every 6 weeks in EGFR positive (Non-small cell lung cancer, NSCLC) with concurrent Driver gene mutations，who used EGFR-TKI with or without combined chemotherapy，estimated with stable efficacy (CR, PR, and SD) .In this study, subjects will be randomly assigned to the following two groups according to a 1:1 ratio:(A) Standard programme group, EGFR-TKI targeted therapy; (B) controlled programme group, EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )

Details

Lead sponsor	The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase	NA
Status	COMPLETED
Enrolment	114
Start date	Mon Nov 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Sep 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Non-small-lung-cell Cancer
• NSCLC
• EGFR Gene Mutation

Interventions

• EGFR-TKI
• EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)

Countries

China